Pfizer BioNTech Announce Early Positive Results in Vaccine Candiate Trial
Pfizer and BioNTech released preliminary results of their Phase 1/2 trial, which suggest that low doses of the vaccine can cause coronavirus-neutralizing antibodies to form; Neil Cavuto and Dr. Devi discuss it on Fox Business.
Previous
Regeneron Says Antibody Cocktail Prevents and Treats Coronavirus in Animals
Next
